Merck KGaA (WBO:MRCK) Change In Receivables: €-132 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

WBO:MRCK Merck KGaA WBO:MRCK
81 GF Score
Price €138.05
GF Value €140.94
Valuation Fairly Valued
! 10 Warning Signs
View Full Analysis

What is Merck KGaA Change In Receivables?

Merck KGaA WBO:MRCK 81 Change In Receivables is €-132 Mil as of Mar. 2026. GuruFocus rates WBO:MRCK with a GF Score™ of 81/100 and a GF Value™ of €140.94 (Fairly Valued). The stock has 10 warning signs investors should review.

Merck KGaA's change in receivables for the quarter that ended in Mar. 2026 was €-263 Mil. It means Merck KGaA's Accounts Receivable increased by €263 Mil from Dec. 2025 to Mar. 2026 .

Merck KGaA's change in receivables for the fiscal year that ended in Dec. 2025 was €-166 Mil. It means Merck KGaA's Accounts Receivable increased by €166 Mil from Dec. 2024 to Dec. 2025 .

Merck KGaA's Accounts Receivable for the quarter that ended in Mar. 2026 was €4,318 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Merck KGaA's Days Sales Outstanding for the three months ended in Mar. 2026 was 76.75.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Merck KGaA's liquidation value for the three months ended in Mar. 2026 was €-13,848 Mil.

Merck KGaA  (WBO:MRCK) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Merck KGaA's Days Sales Outstanding for the quarter that ended in Mar. 2026 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=4318/5134*91
=76.75

2. In Ben Graham's calculation of liquidation value, Merck KGaA's accounts receivable are only considered to be worth 75% of book value:

Merck KGaA's liquidation value for the quarter that ended in Mar. 2026 is calculated as:

Liquidation Value
=Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=3774-23251+0.75 * 4318+0.5 * 4782
=-13,848

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Merck KGaA Change In Receivables Related Terms

Merck KGaA Change In Receivables Historical Data

* Premium members only.

The historical data trend for Merck KGaA's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Merck KGaA Change In Receivables Chart

Merck KGaA Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Change In Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only -310.00 -413.00 -8.00 79.00 -166.00

Merck KGaA Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Change In Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -79.00 -72.00 282.00 -263.00 0.00
WBO:MRCK
81GF Score
Merck KGaA WBO:MRCK
Change In Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Merck KGaA Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-132 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Change In Receivables →
What does a Change In Receivables of €-132 Mil mean?
Merck KGaA (WBO:MRCK) has a Change In Receivables of €-132 Mil as of Mar. 2026. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for Merck KGaA and its competitors.
Is Merck KGaA's Change In Receivables too high?
Merck KGaA's current Change In Receivables is €-132 Mil. Overall, Merck KGaA has a GF Score™ of 81/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Merck KGaA's Change In Receivables compare to ZTS and UTHR?
Merck KGaA's Change In Receivables of €-132 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Receivables for a Drug Manufacturers company?
A good Change In Receivables depends on the Drug Manufacturers industry context. However, Change In Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Receivables mean?
A high Change In Receivables can signal that a stock is expensive relative to its fundamentals. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for Merck KGaA and its competitors. Merck KGaA's current Change In Receivables is €-132 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Merck KGaA stock overvalued right now?
Based on GuruFocus' analysis, Merck KGaA (WBO:MRCK) is currently considered Fairly Valued. The stock's GF Value™ is €140.94, compared to a current price of €138.05 — trading 2.1% below its estimated fair value. The current Change In Receivables is €-132 Mil. Merck KGaA's overall GF Score™ is 81/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Receivables calculated?
Change In Receivables is calculated from a company's financial statements. For Merck KGaA (WBO:MRCK), the current Change In Receivables is €-132 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Merck KGaA (WBO:MRCK) Overvalued in 2026?

Based on GuruFocus' analysis, Merck KGaA stock appears to be undervalued. The current stock price of €138.05 is trading 2.1% below its estimated GF Value™ of €140.94. GuruFocus considers Merck KGaA to be Fairly Valued.

Key valuation signals for WBO:MRCK:

  • Change In Receivables: €-132 Mil
  • GF Value™: €140.94 vs. price of €138.05 (2.1% below fair value)
  • GF Score™: 81/100 with 10 warning signs

No single metric tells the full story. See the WBO:MRCK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Merck KGaA Business Description

Address Frankfurter Strasse 250, Darmstadt, HE, DEU, 64293
Merck KGaA operates in three main segments: Life Science, Electronics, and Healthcare. The Life Science segment provides laboratory consumables and instruments to researchers in academia and applied fields, including the biopharmaceutical industry. The Electronics segment offers specialty materials to manufacture a variety of products, such as semiconductors and flat-screen televisions. In the healthcare segment, Merck develops, manufactures, and sells branded pharmaceuticals with significant therapeutic concentrations in oncology, multiple sclerosis, and fertility. In 1995, the E. Merck KG family publicly sold part of the company, resulting in the current 30% public ownership of the firm.
81GF Score

Get the complete analysis for WBO:MRCK

Change In Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€138.05
Price
€140.94
GF Value